CARTITUDE-1 Study of Cilta-Cel Shows Prolonged PFS Over Other Therapies

Nikhil Munshi, MD, of the Dana-Farber Cancer Institute, who serves as President of the International Myeloma Society, presented close-out data from the CARTITUDE-1 study at the 2023 European Hematology Association (EHA) Congress in Frankfurt, Germany.

In this video interview from the conference, Dr. Munshi shares the close-out efficacy and safety results.

“This is actually the study that led to approval of [ciltacabtagene autoleucel] for relapsed/refractory myeloma,” he said.

The research presented at EHA highlighted progression-free survival (PFS) outcomes and their association with other measures.

“Longer median PFS was observed after a single infusion of cilta-cel than any previously reported therapy in heavily pretreated patients with [relapsed or refractory multiple myeloma],” Dr. Munshi and collegueges wrote in the EHA abstract. “Achieving [complete response] and/or sustained [measurable residual disease] -negativity was associated with prolonged PFS.”